» Articles » PMID: 29196298

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2017 Dec 3
PMID 29196298
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Improved risk assessment for patients with type 2 diabetes and elevated cardiovascular (CV) risk is needed. The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P) predicts a gradient of risk in patients with prior myocardial infarction (MI) but has not been evaluated in patients with type 2 diabetes.

Research Design And Methods: CV event rates were compared by baseline TRS 2°P in 16,488 patients enrolled in SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53) with type 2 diabetes and high CV risk or established CV disease. Calibration was tested in the diabetes cohort from the REACH (REduction of Atherothrombosis for Continued Health) Registry.

Results: TRS 2°P revealed a robust risk gradient for the composite of CV death, MI, and ischemic stroke in the full trial population, with 2-year event rates of 0.9% in the lowest- and 19.8% in the highest-risk groups ( < 0.001). A clear risk gradient was present within the subgroups of all coronary artery disease (CAD), CAD without prior MI, CAD with prior MI, peripheral artery disease, and prior stroke ( < 0.001 for each), with consistent risk relationships across subgroups. The C-statistic (0.71 for CV death and 0.66 for the composite end point) was consistent in each subgroup. There was close calibration with the type 2 diabetes cohort from the REACH Registry (goodness-of-fit = 0.78).

Conclusions: The expanded TRS 2°P provides a practical and well-calibrated risk prediction tool for patients with type 2 diabetes.

Citing Articles

Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data.

Rousset A, Dellamonica D, Menuet R, Lira Pineda A, Sabatine M, Giugliano R Eur Heart J Digit Health. 2023; 3(1):38-48.

PMID: 36713994 PMC: 9707897. DOI: 10.1093/ehjdh/ztab093.


Management and outcomes over time of acute coronary syndrome patients at particularly high cardiovascular risk : the ACSIS registry-based retrospective study.

Grinberg T, Hammer Y, Wiessman M, Perl L, Ovdat T, Tsafrir O BMJ Open. 2022; 12(4):e060953.

PMID: 35410940 PMC: 9003597. DOI: 10.1136/bmjopen-2022-060953.


Environmental noise exposure is associated with atherothrombotic risk.

Koczorowski M, Bernard N, Mauny F, Chague F, Pujol S, Maza M Sci Rep. 2022; 12(1):3151.

PMID: 35210480 PMC: 8873564. DOI: 10.1038/s41598-022-06825-0.


Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.

Sharma A, Zheng Y, Ezekowitz J, Westerhout C, Udell J, Goodman S Diabetes Care. 2021; 45(1):204-212.

PMID: 34716214 PMC: 9004312. DOI: 10.2337/dc20-2806.


Machine learning approaches improve risk stratification for secondary cardiovascular disease prevention in multiethnic patients.

Sarraju A, Ward A, Chung S, Li J, Scheinker D, Rodriguez F Open Heart. 2021; 8(2).

PMID: 34667093 PMC: 8527119. DOI: 10.1136/openhrt-2021-001802.


References
1.
Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

2.
Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011; 162(5):818-825.e6. DOI: 10.1016/j.ahj.2011.08.006. View

3.
Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

4.
Allen L, Matlock D, Shetterly S, Xu S, Levy W, Portalupi L . Use of Risk Models to Predict Death in the Next Year Among Individual Ambulatory Patients With Heart Failure. JAMA Cardiol. 2016; 2(4):435-441. DOI: 10.1001/jamacardio.2016.5036. View

5.
Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth A, Bansal N . Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015; 314(1):52-60. PMC: 4664176. DOI: 10.1001/jama.2015.7008. View